At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 12 enrolled
Drug / intervention
0.5 mg of DE-122 +3 moredrug
Likely dose
0.5 mg of DE-122from record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase I/II, Open-label, Dose-escalating, Sequential-cohort Study Assessing the Safety, Tolerability, Immunogenicity, and Bioactivity of a Single Intravitreal Injection of DE-122 Injectable Solution for the Treatment of Refractory Exudative Age-related Macular Degeneration
In Brief
A Phase 2 clinical trial evaluating 0.5 mg of DE-122, 1.0 mg of DE-122, and 2 other interventions for Age-Related Macular Degeneration. Completed, enrolled 12 participants across 5 sites.
Detailed Summary
The purpose of the study is to evaluate the safety, tolerability, immunogenicity, and bioactivity of a single intravitreal (IVT) administration of DE-122 in subjects with refractory exudative age-related macular degeneration (AMD).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAge-Related Macular Degeneration
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
20162017201820192020202120222023202420252026
Enrollment StartSep 2015
First PostedSep 2015
Primary CompletionAug 2017
TodayJul 2026
First PostedSep 21, 2015
Enrollment StartSep 16, 2015
Primary CompletionAug 1, 2017
TodayJul 2, 2026
Enrollment to primary: 1.9 yearsPosted 10.8 years ago
Interventions
0.5 mg of DE-122drug
DE-122 Injectable Solution
1.0 mg of DE-122drug
DE-122 Injectable Solution
2.0 mg of DE-122drug
DE-122 Injectable Solution
4.0 mg of DE-122drug
DE-122 Injectable Solution